Two drugs, encorafenib and binimetinib, helped melanoma in the brain
Original title: Encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the BECARE (GEM-2002) trial.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
These two drugs are already approved and used for this kind of melanoma today.
The short version
Two drugs taken together shrank brain tumors in many people with a certain melanoma.
What was studied. Doctors in Spain looked back at records of 60 patients at 24 hospitals. All had melanoma with a BRAF: A gene in a pathway that tells cells to divide. Some tumors carry a change in it. There are drugs made to target that change, so your team may test for it. See the glossary gene change that had spread to the brain.
What they found. Tumors shrank in 58.3% of the patients. Among those with no brain symptoms, tumors shrank in 65.4%. Among those with brain symptoms, tumors shrank in 52.9%. Serious side effects from the drugs happened in 12 patients (20%), most often liver test changes.
What this means, and what it doesn't
What it could mean: These two drugs are already a standard choice for this kind of melanoma. This study suggests they can help in normal, everyday care. They seemed to help whether or not a person had brain symptoms.
What it doesn't mean: This was not a new trial. Doctors simply looked back at past records. That kind of study cannot prove the drugs caused the results. It only applies to melanoma with a BRAF: A gene in a pathway that tells cells to divide. Some tumors carry a change in it. There are drugs made to target that change, so your team may test for it. See the glossary gene change, not to other brain tumors. It is not a promise and it is not a cure. The study also hints that radiation may add to the benefit, but the authors say that part still needs real trials.
Source: PubMed, September 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.